Modern Care Journal

Published by: Kowsar

Serum Levels of Insulin-Like Growth Factor 1, Interlukin-6, Heat-Shock Proteins-27 and Heat-Shock Proteins-60 as Inflammatory Markers of Type 2 Diabetes: A Case-Control Study

Arash Ghorbani Abdi Saedabad 1 , Reyhane Rezaie 2 , Seyed Yoosef Javad Moosavi 1 , Gholamraza Anani Sarab 3 , Mohammad Malekaneh 3 and Reyhaneh Houshyar 3 , *
Authors Information
1 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
2 Mashhad University of Medical Sciences, Mashhad, Iran
3 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
Article information
  • Modern Care Journal: January 31, 2019, 16 (1); e80971
  • Published Online: February 12, 2019
  • Article Type: Research Article
  • Received: June 18, 2018
  • Revised: January 1, 2019
  • Accepted: January 14, 2019
  • DOI: 10.5812/modernc.80971

To Cite: Ghorbani Abdi Saedabad A , Rezaie R , Javad Moosavi S Y, Anani Sarab G , Malekaneh M , et al. Serum Levels of Insulin-Like Growth Factor 1, Interlukin-6, Heat-Shock Proteins-27 and Heat-Shock Proteins-60 as Inflammatory Markers of Type 2 Diabetes: A Case-Control Study, Mod Care J. 2019 ; 16(1):e80971. doi: 10.5812/modernc.80971.

Copyright © 2019, Modern Care Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat Rev Drug Discov. 2014;13(6):465-76. doi: 10.1038/nrd4275. [PubMed: 24854413].
  • 2. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on type 2 diabetes prevention. Diabet Med. 2007;24(5):451-63. doi: 10.1111/j.1464-5491.2007.02157.x. [PubMed: 17470191].
  • 3. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006;333(7566):475-80. doi: 10.1136/bmj.38922.650521.80. [PubMed: 16946335]. [PubMed Central: PMC1557968].
  • 4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-34. doi: 10.1001/jama.286.3.327. [PubMed: 11466099].
  • 5. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878-88. doi: 10.1016/j.bbamcr.2011.01.034. [PubMed: 21296109].
  • 6. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: The insulin and IGF connection. Endocr Relat Cancer. 2012;19(5):F27-45. doi: 10.1530/ERC-11-0374. [PubMed: 22593429].
  • 7. Yuan J, Dunn P, Martinus RD. Detection of Hsp60 in saliva and serum from type 2 diabetic and non-diabetic control subjects. Cell Stress Chaperones. 2011;16(6):689-93. doi: 10.1007/s12192-011-0281-7. [PubMed: 21748374]. [PubMed Central: PMC3220386].
  • 8. Kishimoto T. IL-6: From its discovery to clinical applications. Int Immunol. 2010;22(5):347-52. doi: 10.1093/intimm/dxq030. [PubMed: 20410258].
  • 9. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538-42. doi: 10.1016/j.autrev.2009.01.012. [PubMed: 19189867].
  • 10. Mahgoub S, Youns M, Bassyouni A, Hassan Z. Serum levels of heat shock protein 27 as a potential marker of diabetic nephropathy in Egyptians with type 2 diabetes. J Appl Pharm Sci. 2012;2(11):14. doi: 10.7324/japs.2012.21104.
  • 11. Giffard RG, Han RQ, Emery JF, Duan M, Pittet JF. Regulation of apoptotic and inflammatory cell signaling in cerebral ischemia: The complex roles of heat shock protein 70. Anesthesiology. 2008;109(2):339-48. doi: 10.1097/ALN.0b013e31817f4ce0. [PubMed: 18648242]. [PubMed Central: PMC2561962].
  • 12. Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360(2):114-8. doi: 10.1016/j.canlet.2015.02.026. [PubMed: 25721081].
  • 13. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi: 10.1038/nri2925. [PubMed: 21233852].
  • 14. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert C, et al. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr. 2005;82(3):675-84. quiz 714-5. doi: 10.1093/ajcn.82.3.675. [PubMed: 16155283]. [PubMed Central: PMC2563043].
  • 15. Drogan D, Schulze MB, Boeing H, Pischon T. Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus: Results from the EPIC-potsdam study. Am J Epidemiol. 2016;183(6):553-60. doi: 10.1093/aje/kwv188. [PubMed: 26880678].
  • 16. Teppala S, Shankar A. Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care. 2010;33(10):2257-9. doi: 10.2337/dc10-0770. [PubMed: 20639451]. [PubMed Central: PMC2945170].
  • 17. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2008;18(2):166-73. doi: 10.1016/j.ghir.2007.08.004. [PubMed: 17904401]. [PubMed Central: PMC2492581].
  • 18. Deleskog A, Hilding A, Brismar K, Hamsten A, Efendic S, Ostenson CG. Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. Diabetologia. 2012;55(6):1668-78. doi: 10.1007/s00125-012-2529-x. [PubMed: 22426800].
  • 19. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, et al. The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014;51(1):123-31. doi: 10.1007/s00592-013-0543-1. [PubMed: 24370923].
  • 20. Yenari MA, Liu J, Zheng Z, Vexler ZS, Lee JE, Giffard RG. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann N Y Acad Sci. 2005;1053:74-83. doi: 10.1196/annals.1344.007. [PubMed: 16179510].
  • 21. Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): Biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5(1):7. doi: 10.1186/1755-1536-5-7. [PubMed: 22564335]. [PubMed Central: PMC3464729].
  • 22. Gruden G, Bruno G, Chaturvedi N, Burt D, Schalkwijk C, Pinach S, et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: A novel circulating marker for diabetic neuropathy. Diabetes. 2008;57(7):1966-70. doi: 10.2337/db08-0009. [PubMed: 18390793]. [PubMed Central: PMC2453614].
  • 23. Hall L, Martinus RD. Hyperglycaemia and oxidative stress upregulate HSP60 and HSP70 expression in HeLa cells. Springerplus. 2013;2:431. doi: 10.1186/2193-1801-2-431. [PubMed: 24058891]. [PubMed Central: PMC3777022].
  • 24. Imatoh T, Sugie T, Miyazaki M, Tanihara S, Baba M, Momose Y, et al. Is heat shock protein 60 associated with type 2 diabetes mellitus? Diabetes Res Clin Pract. 2009;85(2):208-12. doi: 10.1016/j.diabres.2009.06.004. [PubMed: 19576649].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments